1. Volume 68, Issue 5, Pages 787-794 (November 2015)
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results 
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiri Heracek, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Benoit Baron, Mohammad Hirmand, Matthew R. Smith 
European Urology 
Volume 68, Issue 5, Pages (November 2015)
DOI: /j.eururo
Copyright © 2015 European Association of Urology Terms and Conditions

2. Fig. 1
(A) Mean percentage change in prostate-specific antigen from baseline and (B) mean prostate-specific antigen level by week. Bars show standard deviation.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions

3. Fig. 2
Mean percentage change in luteinizing hormone and testosterone from baseline to week 49.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions